

TABLE 194: FLU-LIKE SYMPTOMS/SUICIDAL IDEATION

| AUTHOR, YEAR, STUDY NAME | GENOTYPE | TREATMENT | FLU-LIKE SYMPTOMS | | | SUICIDAL IDEATION | | |
|----------------------------------|----------|----------------------------|-------------------|-----|-----|-------------------|----|----|
| | | | n | N | % | n | N | % |
| Fried et al., 2013 PILLAR | 1 | (1) PR48 | 29 | 77 | 38% | NR | | |
| | | (42) SIM12 PR24-48 RGT | 18 | 77 | 23% | | | |
| Gane et al., 2013-1 ELECTRON | 2+3 | (3) SOF12 + RBV12 | 0 | 10 | 0% | NR | | |
| | | (40) SOF12 + PR12 | 0 | 11 | 0% | | | |
| Gane et al., 2013-3 ELECTRON | 1 | (3) SOF12 + RBV12 | 0 | 25 | 0% | NR | | |
| Gane et al., 2014-1 ELECTRON | 1 | (10) SOF12 + LDV12 + RBV12 | 0 | 25 | 0% | NR | | |
| Jacobson et al., 2011 ADVANCE | 1 | (1) PR48 | 101 | 361 | 28% | NR | | |
| | | (32) T12 PR24-48 RGT q8 | 102 | 363 | 28% | | | |
| Jacobson et al., 2014 QUEST-1 | 1 | (1) PR48 | 26 | 130 | 20% | NR | | |
| | | (42) SIM12 PR24-48 RGT | 62 | 264 | 23% | | | |
| Kowdley et al., 2013 ATOMIC | 1 | (40) SOF12 + PR12 | 3 | 52 | 6% | NR | | |
| Lawitz et al., 2013-1 PROTON | 1 | (1) PR48 | NR | | | 0 | 26 | 0% |
| | | (41) SOF12 PR24-48 RGT | | | | 1 | 47 | 2% |
| Lawitz et al., 2013-2 PROTON | 2+3 | (40) SOF12 + PR12 | NR | | | 0 | 25 | 0% |
| Lawitz et al., 2013 NEUTRINO | 1+4+5+6 | (40) SOF12 + PR12 | 51 | 327 | 16% | NR | | |
| Lawitz et al., 2013 FISSION | 2+3 | (3) SOF12 + RBV12 | 7 | 256 | 3% | NR | | |
| | | (70) PR24 | 44 | 243 | 18% | | | |
| Lawitz et al., 2014 LONESTAR | 1 | (6) SOF12 + LDV12 | NR | | | 0 | 19 | 0 |
| | | (8) SOF8 + LDV8 | | | | 0 | 20 | 0 |
| | | (9) SOF8 + LDV8 + RBV8 | | | | 0 | 21 | 0 |
| Manns et al., 2014 HALLMARK-DUAL | 1b | (17) DCV24 + ASU24 | 11 | 205 | 5% | NR | | |
| Manns et al., 2014 QUEST-2 | 1 | (1) PR48 | 35 | 134 | 26% | NR | | |
| | | (42) SIM12 PR24-48 RGT | 66 | 257 | 26% | | | |
| Marcellin et al., 2011 | 1 | (32) T12 PR24-48 RGT q8 | 35 | 82 | 43% | NR | | |
| | | (33) T12 PR24-48 RGT q12 | 31 | 79 | 39% | | | |
| Poordad et al., 2011 SPRINT2 | 1 | (1) PR48 | 93 | 363 | 26% | NR | | |
| | | (46) B24 PR28-48 RGT | 91 | 368 | 25% | | | |
| Sulkowski et al., 2014 | 1 | (19) DCV12 + SOF12 | 0 | 41 | 0% | 1 | 41 | 0 |

| AUTHOR, YEAR, STUDY NAME | GENOTYPE | TREATMENT | FLU-LIKE SYMPTOMS | | | SUICIDAL IDEATION | | |
|---|----------|------------------|-------------------|----|-----|-------------------|----|----|
| | | | n | N | % | n | N | % |
| Sulkowski et al., 2013-1+2 ^a | 1 | (1) PR48 | 3 | 22 | 14% | 0 | 22 | 0% |
| | | (39) T12 PR48 q8 | 5 | 38 | 13% | 1 | 38 | 3% |
| Sulkowski et al., 2013 | 1 | (1) PR48 | 13 | 34 | 38% | NR | | |
| | | (50) B44 PR48 | 16 | 64 | 25% | | | |

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; NR = not reported; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

^aData for ineligible participants who receive efavirenz-based antiretroviral and 1,125 mg of telaprevir every 8 hours are also included.